Genprex is developing a robust pipeline of drugs, headlined by its non-small cell lung cancer (NSCLC) drug candidate GPX-001, formerly known as Oncoprex. The drug works by interrupting cell signaling pathways that cause the replication and proliferation of cancer cells.